Australian Doctor Australian Doctor 7th July 2017 | Page 14

The DPP4 inhibitor that simplifies the T2D journey
1
TRAJENTA® does not require dose adjustment, regardless of renal function. 1
5
mg
Regardless of
renal function 1
Even in hepatic
impairment 1
Any age
≥18 years 1
once daily
Safety and tolerability
similar to placebo 1
Independent of
disease duration 1
With a broad range
of PBS listings 2
Dual therapy
(linagliptin + metformin OR SU)
Triple Therapy
(linagliptin + metformin AND SU)
Add-on to insulin
Start simple. Stay simple. 1
PBS Information: TRAJENTA ® : Authority Required (STREAMLINED).
Type 2 Diabetes. Code 6346 – Add-on to metformin or SU. Code 6363 – Triple therapy (with metformin and SU).
Code 6376 – Add-on to insulin. Refer to PBS Schedule for full Authority Required Information.
BEFORE PRESCRIBING, PLEASE REVIEW THE FULL PRODUCT INFORMATION WHICH IS AVAILABLE ON REQUEST FROM BOEHRINGER
INGELHEIM OR FROM WWW.BOEHRINGER-INGELHEIM.COM.AU/PI
Boehringer Ingelheim Pty Limited, ABN 52 000 452 308.
78 Waterloo Road, North Ryde, NSW 2113 Australia. Copyright © 2017.
BOEH0717 AU/TRJ/00254a Prepared May 2017.
TRAJENTA ® (linagliptin) 5mg film-coated tablets. INDICATION: Trajenta is indicated in adult patients with type 2 diabetes mellitus to improve glycaemic control in conjunction with diet and exercise. Monotherapy when metformin and
sulfonylureas are not tolerated, or are contraindicated. Add on to metformin, sulfonylureas or metformin plus sulfonylureas, or to insulin (with or without metformin). CONTRAINDICATIONS: Hypersensitivity to linagliptin or to any of the excipients.
PRECAUTIONS: Not for use in type 1 diabetes, diabetic ketoacidosis. Discontinue if pancreatitis or bullous pemphigoid is suspected. Risk of hypoglycaemia when used in combination with sulfonylureas and insulin; pregnancy; lactation;
children < 18 years. INTERACTIONS: Antagonised by strong P-gp or CYP3A4 inducers. Others, see full PI. ADVERSE REACTIONS: Very common: combination with metformin and a sulfonylurea and combination with insulin – hypoglycaemia;
Common: increase in uric acid, increase in lipase; combination with metformin – arthralgia, back pain, headache; combination with a sulfonylurea – nasopharyngitis, hypertriglyceridaemia, urinary tract infections; combination with metformin and
a sulfonylurea – cough. Others, see full PI. DOSAGE AND ADMINISTRATION: 5 mg once daily taken with or without food. No dose adjustment is necessary for the elderly, or patients with renal or hepatic impairment. Boehringer Ingelheim Pty Limited
ABN 52 000 452 308 78 Waterloo Road North Ryde NSW 2113. February 2017.
References: 1. TRAJENTA ® Approved Product information. 2. Schedule of Pharmaceutical Benefits. Available at: www.pbs.gov.au. Accessed May 2017.
Eli Lilly Australia Pty Limited, ABN 39 000 233 992.
112 Wharf Road, West Ryde, NSW 2114 Australia.
Copyright © 2017